HRP20201832T1 - Sustavi aditiva za upotrebu u pegilaciji proteina - Google Patents
Sustavi aditiva za upotrebu u pegilaciji proteina Download PDFInfo
- Publication number
- HRP20201832T1 HRP20201832T1 HRP20201832TT HRP20201832T HRP20201832T1 HR P20201832 T1 HRP20201832 T1 HR P20201832T1 HR P20201832T T HRP20201832T T HR P20201832TT HR P20201832 T HRP20201832 T HR P20201832T HR P20201832 T1 HRP20201832 T1 HR P20201832T1
- Authority
- HR
- Croatia
- Prior art keywords
- protein
- peg
- aminobenzoic acid
- acid hydrazide
- additive system
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/64—Relaxins
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562258644P | 2015-11-23 | 2015-11-23 | |
| PCT/US2016/063313 WO2017091568A1 (en) | 2015-11-23 | 2016-11-22 | Additive systems for use in protein pegylation |
| EP16816042.2A EP3380487B1 (en) | 2015-11-23 | 2016-11-22 | Additive systems for use in protein pegylation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201832T1 true HRP20201832T1 (hr) | 2021-01-08 |
Family
ID=57589163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201832TT HRP20201832T1 (hr) | 2015-11-23 | 2016-11-22 | Sustavi aditiva za upotrebu u pegilaciji proteina |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10617765B2 (enExample) |
| EP (2) | EP3789395B1 (enExample) |
| JP (2) | JP6921821B2 (enExample) |
| KR (1) | KR102688003B1 (enExample) |
| CN (2) | CN108350025B (enExample) |
| CY (1) | CY1123699T1 (enExample) |
| DK (1) | DK3380487T3 (enExample) |
| ES (1) | ES2827776T3 (enExample) |
| HR (1) | HRP20201832T1 (enExample) |
| HU (1) | HUE052634T2 (enExample) |
| LT (1) | LT3380487T (enExample) |
| PL (1) | PL3380487T3 (enExample) |
| PT (1) | PT3380487T (enExample) |
| RS (1) | RS61072B1 (enExample) |
| SI (1) | SI3380487T1 (enExample) |
| SM (1) | SMT202000649T1 (enExample) |
| WO (1) | WO2017091568A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017091568A1 (en) * | 2015-11-23 | 2017-06-01 | Bristol-Myers Squibb Company | Additive systems for use in protein pegylation |
| LT3849614T (lt) * | 2018-09-11 | 2024-03-25 | Ambrx, Inc. | Interleukino-2 polipeptido konjugatai ir jų panaudojimas |
| CN111484551B (zh) * | 2020-03-19 | 2022-02-11 | 北京翼方生物科技有限责任公司 | 一种聚乙二醇修饰的重组人碱性成纤维细胞生长因子 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19535571A1 (de) | 1995-09-14 | 1997-03-20 | Boehringer Mannheim Gmbh | Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten |
| TWI240627B (en) | 1996-04-26 | 2005-10-01 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
| EP0885613A1 (de) | 1997-06-21 | 1998-12-23 | Roche Diagnostics GmbH | Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin |
| DE19734293A1 (de) | 1997-08-08 | 1999-02-11 | Boehringer Mannheim Gmbh | Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen |
| JP5460958B2 (ja) * | 2004-03-17 | 2014-04-02 | アンチキャンサー インコーポレーテッド | タンパク質ポリエチレングリコール（ｐｅｇ）複合体形成を増大させる方法 |
| TW200722521A (en) * | 2005-06-01 | 2007-06-16 | Alza Corp | Novel bioconjugation reactions for acylating polyethylene glycol reagents |
| JP5508716B2 (ja) * | 2005-11-08 | 2014-06-04 | アンブルックス，インコーポレイテッド | 非天然アミノ酸、および非天然アミノ酸ポリペプチドを修飾するための促進剤 |
| ES2385114T3 (es) * | 2007-03-30 | 2012-07-18 | Ambrx, Inc. | Polipéptidos de FGF-21 modificados y sus usos |
| CA2899448C (en) | 2013-01-30 | 2021-10-26 | Avelas Biosciences, Inc. | Selective delivery molecules and methods of use |
| HK1222122A1 (zh) | 2013-04-22 | 2017-06-23 | Avelas Biosciences, Inc. | 选择性药物递送组合物及使用方法 |
| SG11201702824UA (en) | 2014-10-24 | 2017-05-30 | Bristol Myers Squibb Co | Modified fgf-21 polypeptides and uses thereof |
| WO2017091568A1 (en) * | 2015-11-23 | 2017-06-01 | Bristol-Myers Squibb Company | Additive systems for use in protein pegylation |
-
2016
- 2016-11-22 WO PCT/US2016/063313 patent/WO2017091568A1/en not_active Ceased
- 2016-11-22 ES ES16816042T patent/ES2827776T3/es active Active
- 2016-11-22 PL PL16816042T patent/PL3380487T3/pl unknown
- 2016-11-22 DK DK16816042.2T patent/DK3380487T3/da active
- 2016-11-22 US US15/776,923 patent/US10617765B2/en active Active
- 2016-11-22 RS RS20201382A patent/RS61072B1/sr unknown
- 2016-11-22 EP EP20189107.4A patent/EP3789395B1/en active Active
- 2016-11-22 KR KR1020187017508A patent/KR102688003B1/ko active Active
- 2016-11-22 HR HRP20201832TT patent/HRP20201832T1/hr unknown
- 2016-11-22 HU HUE16816042A patent/HUE052634T2/hu unknown
- 2016-11-22 PT PT168160422T patent/PT3380487T/pt unknown
- 2016-11-22 SI SI201630957T patent/SI3380487T1/sl unknown
- 2016-11-22 CN CN201680067897.7A patent/CN108350025B/zh active Active
- 2016-11-22 CN CN202211743414.4A patent/CN115819494A/zh active Pending
- 2016-11-22 LT LTEP16816042.2T patent/LT3380487T/lt unknown
- 2016-11-22 JP JP2018526713A patent/JP6921821B2/ja active Active
- 2016-11-22 EP EP16816042.2A patent/EP3380487B1/en active Active
- 2016-11-22 SM SM20200649T patent/SMT202000649T1/it unknown
-
2020
- 2020-02-21 US US16/797,361 patent/US11213589B2/en active Active
- 2020-11-20 CY CY20201101102T patent/CY1123699T1/el unknown
-
2021
- 2021-07-28 JP JP2021123154A patent/JP7257457B2/ja active Active
- 2021-12-03 US US17/541,636 patent/US20220160883A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20220160883A1 (en) | 2022-05-26 |
| US10617765B2 (en) | 2020-04-14 |
| JP2021176890A (ja) | 2021-11-11 |
| US20200276319A1 (en) | 2020-09-03 |
| EP3789395B1 (en) | 2025-08-27 |
| CY1123699T1 (el) | 2022-03-24 |
| ES2827776T3 (es) | 2021-05-24 |
| US11213589B2 (en) | 2022-01-04 |
| DK3380487T3 (da) | 2020-12-07 |
| CN115819494A (zh) | 2023-03-21 |
| SI3380487T1 (sl) | 2020-11-30 |
| CN108350025B (zh) | 2023-02-21 |
| EP3789395A1 (en) | 2021-03-10 |
| US20190351065A1 (en) | 2019-11-21 |
| RS61072B1 (sr) | 2020-12-31 |
| JP2019503994A (ja) | 2019-02-14 |
| CN108350025A (zh) | 2018-07-31 |
| KR20180081610A (ko) | 2018-07-16 |
| JP7257457B2 (ja) | 2023-04-13 |
| SMT202000649T1 (it) | 2021-01-05 |
| LT3380487T (lt) | 2020-12-28 |
| EP3380487A1 (en) | 2018-10-03 |
| KR102688003B1 (ko) | 2024-07-23 |
| PT3380487T (pt) | 2020-10-29 |
| HUE052634T2 (hu) | 2021-05-28 |
| PL3380487T3 (pl) | 2020-12-28 |
| WO2017091568A8 (en) | 2018-01-04 |
| JP6921821B2 (ja) | 2021-08-18 |
| WO2017091568A1 (en) | 2017-06-01 |
| EP3380487B1 (en) | 2020-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201832T1 (hr) | Sustavi aditiva za upotrebu u pegilaciji proteina | |
| JP2017061474A5 (enExample) | ||
| FI3694529T3 (fi) | Trispesifiset proteiinit ja niiden käyttömenetelmät | |
| PE20171181A1 (es) | Complejos radiofarmaceuticos | |
| HRP20230260T1 (hr) | Glikoinženjering ciljajućih dijelova specifičan za mjesto | |
| HRP20220455T1 (hr) | Modificirane aminokiseline koje sadrže azid grupu | |
| MX2018004938A (es) | Vacunas de antigeno ligado a pcrv de p. aeruginosa. | |
| EP3326005A4 (en) | SYSTEM AND METHOD FOR LOCALIZING AND TRACKING WITH GNSS POSITION ESTIMATES, SNR SATELLITE DATA AND 3D CARDS | |
| UA102061C2 (ru) | Агонистическое антитело к notch3 и его применение для лечения notch3- ассоциированных заболеваний | |
| CL2019003410A1 (es) | Péptido asociado a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprende el péptido; método para producir el péptido; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407). | |
| NZ713602A (en) | Method for refining protein including self-cutting cassette and use thereof | |
| BR112015026314A2 (pt) | composto líquido iônico | |
| FI3380115T3 (fi) | Peptidejä piwil1:stä | |
| JP2019503994A5 (enExample) | ||
| ZA202210624B (en) | Anti-cd137 construct and use thereof | |
| MX388855B (es) | Hidrogenacion catalitica de cianopiridinas sustituidas y proceso para la preparacion de piridilmetilbenzamidas sustituidas. | |
| CN101903047A (zh) | 生物分子的选择性放射性标记 | |
| JP2017037014A5 (enExample) | ||
| ATE504289T1 (de) | Ausstossflüssigkeit und ausstossverfahren | |
| Dyer et al. | Improved quantification of the cyanobacteria metabolite, β-methylamino-l-alanine (BMAA) using HPLC-MS/MS detection of its dansyl chloride derivative referenced to a 15 N-labeled internal standard | |
| HRP20202077T1 (hr) | Postupak za pročišćavanje pegiliranog eritropoetina | |
| MX2019006363A (es) | Metodo para la polialcoxilacion de acidos nucleicos que permite la recuperacion y reutilizacion del reactivo de polialcoxilacion en exceso. | |
| TH168515A (th) | พิร์โรลิดีนซึ่งเป็นตัวปรับของ gpr40 สำหรับรักษาโรค เช่น โรคเบาหวาน | |
| Kuziv et al. | 6-sulfobenzotriazole as a new reagent for amide bond formation in aqueous medium. | |
| TH1701003363A (th) | สารเชิงซ้อนเภสัชรังสี |